AHAS1: A pilot trial to determine whether reduced dose intravenous Abciximab achieves optimal platelet inhibition in acute ischemic stroke "AHAS1"


Phase N/A Results N/A

Eligibility Criteria

Inclusion Criteria

1. Age 18+ years. 2. Suffer from a suspected large artery or cardioembolic ischemic stroke within the last six hours for anterior circulation and within 12 hours for posterior circulation strokes. 3. Ineligible for treatment with IV rt-PA.

Exclusion Criteria

1. Initial CT of the head suggests symptoms are not due to an ischemic stroke. 2. Platelet count < 100,000. 3. PTT >75. 4. INR > 2.5. 5. ACT >250. 6. AST or ALT > 3X normal values. 7. Creatinine > 2. 8. Treatment team considers the patient to be at increased risk of intracerebral hemorrhages or systemic bleeding. 9. Estimated pre-morbid modified Rankin Score (mRS) > 2.